Market Overview

A Peek Into The Market Before The Trading Starts

Share:
A Peek Into The Market Before The Trading Starts
Related AAPL
Why This Fund Manager Is Reducing His Exposure To Apple
Biomonitoring Is The New Black
Ways To Think About Market Size (Seeking Alpha)
Related SWK
Fast Money Halftime Report Final Trade From February 17
Imperial Capital Raises Price Target On Stanley Black & Decker Following 4Q14 Results
Some Companies Are More Wonderful Than Others (Seeking Alpha)

Pre-open movers US stock futures are mixed this morning, after disappointing results from Apple (NASDAQ: AAPL). Futures for the Dow Jones Industrial Average gained 2 points to 13,720.00 and S&P 500 index futures fell 3.30 points to 1,487.00. Nasdaq 100 futures tumbled 37.75 points to 2,721.25.

A Peek Into Global Markets European markets were mostly lower today. The STOXX Europe 600 Index fell 0.10%, London's FTSE 100 Index gained 0.28%, German DAX 30 Index fell 0.18% and French CAC 40 Index declined 0.01%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average rising 1.28%, China's Shanghai Composite dropping 0.79% and Australia's S&P/ASX 200 Index climbing 0.45%. Hong Kong's Hang Seng Index dropped 0.15% and India's Sensex declined 0.51%.

Broker Recommendation Analysts at Jefferies downgraded Apple (NASDAQ: AAPL) from “buy” to “hold.” The target price for Apple has been lowered from $800 to $500.

Apple shares fell 9.53% to $465.00 in pre-market trading.

Breaking news

  • Stanley Black & Decker (NYSE: SWK) reported a rise in its fourth-quarter earnings. For 2013, it projects adjusted earnings of $5.40 to $5.65 per share, versus analysts' estimates of $5.69 per share. To read the full news, click here.
  • The Board of Directors of Precision Castparts (NYSE: PCP) has approved a $750 million program to repurchase shares of PCP's common stock, effective immediately and continuing through June 30, 2015. To read the full news, click here.
  • Biodel (NASDAQ: BIOD) today announced positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to evaluate the pharmacokinetic and injection site toleration profiles relative to Humalog®, a rapid-acting insulin analog. To read the full news, click here.
  • Researchers from IBM (NYSE: IBM) and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact. To read the full news, click here.

Posted-In: Jefferies US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (AAPL + BIOD)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→